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1. Introduction 
Essential hypertension affects 20-30% of the population worldwide and contributes 
significantly to mortality and morbidity[1] from cerebrovascular diseases, myocardial 
infarction, congestive heart failure and renal insufficiency. Essential hypertension is a 
prevalent disorder that leads to significant morbidity and mortality. Essential hypertension 
is defined as chronically elevated arterial pressure resulting from an unknown etiology. 
Intrinsically, it is a complex, heterogeneous, multifactorial syndrome to which 
environmental factors are partly responsible for. A lineup of aberrant environmental factors, 
including dietary salt intake[2,3,4], body weight[5,6], physical inactivity[7.8], physical stress[9.10], 
cigarette smoking [11-14], alcohol consumption[15-18] and inadequate potassium 
consumption[19,20] contribute to essential hypertension, possibly by infuriating genetically 
programmed susceptibilities. Results from twins, adoptive and population studies suggest 
high degree of similarity of blood pressure values, thus indicating the importance of genetic 
variables in essential hypertension etiology[21-25]. It is assumed that blood pressure is under 
the control of a large number of genes each of which has only relatively mild effects. 
Despite progress in genomic and statistical tools, identification of genes involved in complex 
cardiovascular traits such as hypertension remains a major challenge. Several strategies 
have been developed so far. Of these approaches developed, gene expression techniques 
hold vast promises as functional roles of gene products are determined among diverse 
biological processes[26]. Gene expression profiling has become an overshadowing tool for 
discovery in medicine. Genes have additive function of working together; therefore 
expression levels of these groups of gene can be monitored through gene expression studies. 
At present, differential gene expression between two sets of biological samples is carried out 
by utilizing techniques such as Northern blot analysis, serial analysis of gene expression 
(SAGE), differential display reverse transcription-PCR (DDRT-PCR) and Dot Blot analysis 
[26,27]. The drawback of these techniques is that large numbers of genes cannot be analyzed 
simultaneously. What’s more, with Northern blot limited number of mRNAs may be 
examined simultaneously and quality and quantification of expression are negatively 
affected[28].  Although the strengths of SAGE are remarkable, extensive DNA sequencing is 
technically difficult and formidable. With DDRT-PCR, simultaneous discovery of multiple 
differences in gene expression is possible; however, screening is not based on identity but in 
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mRNA length[29]. Dot blot analysis is less time consuming, however, no information on the 
size of the target biomolecules is offered. 
DNA microarray technology has the potential to overcome these limitations, as it has 
allowed unprecedented analysis of thousands of genes in a high-throughput form. On 
account of its high-throughput expression profiling, DNA microarray technology has 
become the predominant assay of choice in clinical medicine. This review, to a great extent 
looks at studies that used gene expression microarray technology in hypertension research 
to provide information on the disease specific risk profiles and pathology. 
2. Methods 
A literature search of the PUBMED database, using the medical headings “hypertension,” 
“blood pressure,” “gene expression,” and” microarray analysis,” will be conducted. The 
search will include published studies in human beings and as well as experimental models. 
Additionally, a search will be performed using references cited in original study articles and 
reviews and if copies of articles cannot be accessed, authors will be contacted. 
2.1 Methods for the study of gene expression 
Methods used to profile gene expression include Northern blot analysis, serial analysis of 
gene expression, differential display, dot blot analysis, subtractive hybridization and 
microarray hybridization. 
2.2 Northern blot analysis 
Although more sensitive gene expression techniques have emerged over the last decade, 
Northern blot analysis remains the standard for detection and quantitation of mRNA. 
Northern blotting has proven very effective in evaluating the expression levels of 
troponin c in chicken skeleton and cardiac muscles[30], arterial natriuretic factor  mRNA 
and peptide in the human heart during development [31], myosin heavy chain and actin[32].  
It is remarkable in that it allows a direct relative comparison of message abundance 
between samples on a single blot. Regrettably, this technique requires large quantities of 
RNA and is prone to significant experimental manipulation for each of the genes 
examined.  Taniguchi et al compared Northern blotting analyses with DNA microarrays 
and discovered Northern blotting to be more sensitive and consistent than DNA 
microarrays[33]. Despite the fact large-scale transcriptome analysis experiments are not 
performable with Northern blotting, it is however, conveniently used in studies focused 
on analysis of small numbers of genes. 
2.3 Serial analysis of gene expression (SAGE) 
Serial analysis of gene expression method was recently discovered at John Hopkins 
University with the intention to create a global picture of cellular function.  SAGE enables 
tagged short sequences of reverse transcribed cDNA to be prepared and identified by DNA 
sequencing[34]. The SAGE technique can be used to obtain large-scale cardiac gene 
expression[35,36]. Even supposing the quantitative and cumulative data this technique 
presents, one limitation is the identification of the genes reported by the SAGE. 
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2.4 Differential Display (DD) 
Differential display was first introduced by Liang and Pardee in 1992[37]. This technique 
involves the identification and analysis of differentially expressed genes at the mRNA level. 
The basic principle of differential display is to use short primers in combination with oligo-
dT primers to amplify and visualize mRNA in a cell. DD has been a powerful and successful 
method due to its inherent simplicity to detect changes in mRNA profiles among multiple 
samples without any prior knowledge of genomic information of the organism studied. 
2.5 Dot blot analysis 
Dot blot is an immunological technique and is a simplification of northern blotting, southern 
blotting, or western blotting methods[38,39]. This method identifies a known protein in a 
biological sample. Dot blot differs from western blotting in that protein samples are 
separated electrophoretically but are spotted through circular templates directly onto the 
membrane or paper substrate. The characteristic of dot blot is the use of immunodetection to 
identify a specific protein. 
2.6 Subtractive hybridization 
Subtractive hybridization is a powerful technique that was first described by Sargent and 
Dawid for creating cDNA libraries and generating probes of genes expressed differentially 
[40]. This technique is based on the principle that nucleic acid sequences in common with the 
two populations can form hybrids. It is the first tool used for identifying differentially 
expressed genes on a global scale. With Subtractive hybridization, the isolation of genes 
does not require prior knowledge of their sequence or identity. 
2.7 Microarray hybridization 
Microarray analysis, is a high through-put technique that provides an important tool to 
study the global patterns of gene expression. Two of the most commonly used microarrays 
for gene-expression measurements are oligonucleotide GeneChip expression arrays by 
Affymetrix and cDNA microarrays. Oligonucleotide microarrays contain sets of multiple 25 
mer oligonucleotide probes specific for each gene or expressed-sequence tag (EST), whereas 
cDNA microarrays generally contain longer oligonucleotide probes (usually 25 to 60 bases) 
or cDNA probes (usually 500 to 1,000 bases) that stand for the specific gene, so cDNA 
microarrays are more commonly used. It permits quantitative analysis of RNAs transcribed 
from both known and unknown genes. Microarray analysis is based on the principle of 
complementary, single-stranded, nucleic acid sequences forming double-stranded hybrids. 
This technology can simultaneously measure the expression levels of thousands of genes 
within a particular mRNA sample in a high-through put manner[42,43]. 
2.8 Research objects 
For the DNA microarrays, we could study human or animal models. The spontaneously 
hypertensive rats (SHR) are the most popular used animal models for essential 
hypertension, and the Lyon hypertensive rats[44] follows behind, compared to normotensive 
Wistar Kyoto rats (WKY).  
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2.9 Samples 
We mainly use peripheral blood samples[45] in human and vascular smooth muscle cell 
(VSMC) [46,47], adrenal[44], heart[2,48,49]  and kidney[2,44,53-56,58]  in animal models. 
2.10 Software tools 
The large amount of information generated from microarrays has been a great strength, but 
is sometimes seen as a frustrating weakness because of the inability to process experimental 
data easily, assess the data quality, manage multiple data sets and mine the data with user-
friendly tools. Most of the microarrays have the suite of software to deal with the results, 
such as the Affymetrix software for the Affymetrix microarrays. The related software is 
listed as follows. The software was not designed to do complex statistical analyses and 
visualization. Rather, it was designed to help the researcher narrow their search from tens of 
thousands of gene candidates to several hundred or fewer that meet specific, but adjustable 
criteria. 
2.11 Altered gene expression in blood 
Peripheral blood gene expression has the potential to provide information on underlying 
pathologic states. Several authors have used whole blood as a surrogate tissue for gene 
expression in patients with essential hypertension. In their study, Korkor et al identified 49 
differentially expressed genes; 31 up regulated and 18 down regulated genes. Amongst 
genes found to be altered include CD36, SLC4A1, NET1, SESN3, ZNF652, PRDX6, HIP1, 
FOLR3, ERAP1, CFD[45]. Most of the genes that were differentially expressed were related to 
immune/inflammatory responses. In a study conducted by Chon et al, gene expression 
patterns of hypertensives revealed 680 genes that were upregulated as compared to patients 
who were normotensive on medication [52]. Timofeeva AV et al reported that 22 genes were 
up-regulated  and 18 genes down-regulation in atherosclerotic aorta compared with normal 
vessel through cDNA microarray, among these, CD53, SPI1, FPRL2, SPP1, CTSD, ACP5, 
LCP1, CTSA and LIPA genes are up-regulated both in peripheral blood leukocytes from EH 
patients and in atherosclerotic lesions of human aorta. The majority of these genes 
significantly positively correlated with hypertension stage as well as with histological 
grading of atherosclerotic lesions[53]. 
2.12 Altered gene expression in the tissues and organs 
Koo et al reported altered gene expression in the kidneys of adults of spontaneously 
hypertension rats[54]. Analyzing mRNA from 8-week-old female SHR and age-matched 
female WKY, 43 up-regulated and 31 down-regulated genes were revealed.  The 
upregulation of stearoyl-COA desaturase-2 gene and downregulation of taurine/beta-
alanine transporter gene in SHR compared with WKY rat were reported and in the SHR 
group, dysregulations of several genes involved in lipid metabolism was also revealed. 
Seubert et al investigated renal gene expression profiles in SHR and WKY animals at 
prehypertensiive (3 wk of age) and hypertensive (9 wk of age) stages and identified 22 genes 
at 3 wk of age and 104 genes at 9 wk of age that were differentially expressed in SHR 
compared with WKY[55]. There are some other studies identified differential gene expression 
in animal models of essential hypertension that are listed in table 2. 
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Results References 
49 genes were found differentially expressed in essential 
hypertension, 31 up regulated and 18 down regulated. 
Korkor et al. 
(45) 
680 genes were found differentially expressed in untreated 
hypertensives compared to normotensive controls. On the other hand, 
only 7 genes were differentially expressed in treated hypertensives 
compared to normotensive controls. 
Chen et al. (52) 
22 genes were up-regulated  and 18 genes demonstrated down-
regulation in atherosclerotic aorta compared with normal vessel, 
CD53, SPI1, FPRL2, SPP1, CTSD, ACP5, LCP1, CTSA and LIPA genes 
are up-regulated in peripheral blood leukocytes from EH patients and 
in atherosclerotic lesions of human aorta. The majority of these genes 
significantly (p<0.005) positively (r>0.5) correlated with AH stage as 
well as with histological grading of atherosclerotic lesions. 
Timofeeva AV 
et al (53) 
 
Table 1. Differential gene expression profiling in human blood in essential hypertension.  
 
 
 
Animal model 
and the control 
group 
Tissue Microarray 
platform 
Software Observations References 
SDR, SHR and 
WKY 
Area 
postrema 
Rat Genechip 
230 2.0 
microarrys 
GeneSpring GX11 'hypertension-related' 
elements revealed 
genes that are involved 
in the regulation of 
both blood pressure 
and immune function 
Hindmarch 
CC et al. 
(46) 
eET-1 and wild-
type (WT) mice 
mesenteric 
arteries 
Ilumina 
microarray, 
validation by 
qPCR of 4 
genes 
Flexarray software 
for the microarray 
results, and Ingenuity 
Pathway Analysis for 
the gene lists. 
increased endothelial 
ET-1 expression results 
in early changes in 
gene expression in the 
vascular wall that 
enhance lipid 
biosynthesis and 
accelerate progression 
of atherosclerosis. 
Simeone 
SM et al. 
(47) 
SHR and BNR 
for the control 
Kidney Affymetrix 
U34A-C 
microarrays, 
validation by 
RT-PCR, 
DNA 
sequencing 
and RFLP 
analyses. 
Solexa Tag analysis 88 transcripts are 
identified to be 
differentially 
expressed between 
SHRs and BN rats. 
Johnson 
MD et al. 
(2) 
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Animal model 
and the control 
group 
Tissue Microarray 
platform 
Software Observations References 
normal 
(normotensive) 
Wistar rats, 
DOCA–salt 
hypertensive 
(DH) rats,  DH 
rats treated with 
AG1478, and 
DH rats treated 
with FPTIII 
kidney Codelink 
Uniset Rat 
1Bioarrays 
Affymetrix Scanner 
428, Imagene and 
Genowiz softwares 
by Ocimum 
Biosolutions (India) 
and subjected to 
arsinh transformation
2398 genes were 
upregulated and only 
50 genes were 
downregulated by 
more than 2-fold in 
hypertensive rat 
kidneys compared to 
non-diseased controls.  
Benter IF et 
al. (44) 
SHR aorta GeneChip® 
Affymetrix 
Rat Genome 
Rat Genome 
230 2.0 Array 
GeneChip®Operating
Software Version 1.4, 
Affymetrix analyzer. 
Thirty-nine genes that 
showed more than a 2-
fold increase in 
expression after 
administration of VPP 
and IPP, Fourteen 
genes that showed less 
than a 0.5-fold 
decrease in expression 
Yamaguchi 
N et al. (48) 
SHR and WKY  brain, 
heart, 
kidney 
and liver 
UniSet Rat I 
Expression 
Bioarray, 
validation by 
RT-PCR of 9 
genes 
F-test and unpaired t 
test. CodeLink 
Expression Analysis 
Software, GenePix 
Pro 6.0 Software, 
GeneSpring software
60 genes were 
differentially 
expressed in the heart 
of SHRSP rats. Of 
these, five genes were 
up-regulated and 55 
genes were down-
regulated. 
Kato N et 
al. (51) 
SHR, LHR, 
heterozygous 
TGR(mRen2)27 
rat, and their 
respective 
controls 
heart Affymetrix 
GeneChip 
Rat 
Expression 
Array 
RAE230A, 
validation by 
qPCR of 6 
genes. 
Affymetrix 
Microarray Suite 5.0 
software, significance 
analysis of 
microarrays (SAM) 
1.21 software 
Only four genes had 
significantly modified 
expression in the three 
hypertensive models 
among which a single 
gene, coding for 
sialyltransferase 7A, 
was consistently 
overexpressed 
Cerutti C et 
al. (49) 
WKY Kidney 
and aorta.
Affymetrix 
rat genome 
230A array, 
validation by 
RT-PCR 
software R together 
with its 
bioinformatics 
packages collected in 
the Bioconductor 
project 
Six functionally known 
genes (Igfbp1, Xdh, 
Sult1a1, Mawbp, Por, 
and Gstm1) and two 
expressed sequence 
tages (BI277460 and 
AI411345) were 
significantly 
upregulated 
Westhoff 
TH et al. 
(56) 
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Animal model 
and the control 
group 
Tissue Microarray 
platform 
Software Observations References 
Female C57Bl/6J 
mice 
Blood, 
heart and 
liver 
Mouse NIH 
15K cDNA 
microarrays 
Expression Profiler 
tool EPCLUST 
L-NNA and BSO both 
caused hypertension. 
Gene expression was 
regulated in 
cytoskeletal 
components in both 
models, protein 
synthesis in L-NNA-
treated mice, and 
energy metabolism in 
BSO-treated mice. 
Chon H et 
al. (41) 
SHR and WKY  kidney Affymetrix 
rat RG-U34A 
array 
Normalisation and 
scaling using 
GeneChip suite. 
20 genes were down-
regulated and 7 genes 
were up-regulated in 
SHR 
Hinojos CA 
et al. (50) 
SHR and WKY  heart Affymetrix 
Rat Genome 
U34A 
GeneChips 
Affymetrix software, 
GeneSpring software
Comparison of LV 
RNA profiles from 20- 
and 12-month-old SHR 
identified 61 known 
genes and 20 ESTs, 
whose expression was 
upregulated >1.5-fold, 
and 31 known genes 
and 15 ESTs, whose 
expression was 
downregulated >1.5-
fold. 
Rysä J et al. 
(57) 
Sabra rat kidney Affymetrix 
Rat Genome 
RAE230 
GeneChip, 
validation by 
RT-PCR of 7 
genes. 
Affymetrix software 2470 transcripts were 
differentially 
expressed between the 
study groups. Cluster 
analysis identified 
genome-wide 192 
genes that were 
relevant to salt-
susceptibility and/or 
hypertension, 19 of 
which mapped to 
chromosome 1. 
Yagil C et 
al. (58) 
Nppa+/+ and 
Nppa−/- mice 
Heart, 
Lung, 
kidney, 
brain, 
liver, and 
spleen 
mouse 
microarray 
membranes 
(GeneFilter 
GF-400 
membranes) 
software package Expression of 80 genes 
was elevated >2-fold 
and expression of 10 
was reduced to <0.5 in 
7-day TAC Nppa+/+ 
compared with control 
Dajun 
Wang et al. 
(59) 
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Animal model 
and the control 
group 
Tissue Microarray 
platform 
Software Observations References 
SHR and WKY  Kidney, 
spleen, 
and liver 
Affymetrix 
Rat U34 array 
set validation 
by qRT-PCR 
Affymetrix MAS 5.0 There was a significant 
reduction in 
expression of 
glutathione S-
transferase mu-type 2, 
a gene involved in the 
defense against 
oxidative stress
Martin W. 
McBride et 
al. (60) 
SHR kidney Affymetrix 
Rat Genome 
U34A arrays 
Software packge Of the 8,799 known 
genes and expressed 
sequence tag (EST) 
clusters of Affymetrix 
Rat Genome U34A 
arrays, 74 differentially 
expressed transcripts, 
of which 43 were up-
regulated and 31 were 
down-regulated in 
SHR.
Koo et al. 
(54) 
SHR and WKY kidney cDNA Rat 
version 2.0 
Chip, 
validation by 
Northern blot 
and RT-PCR 
ArraySuite version 
2.0 
22 genes at 3 weeks of 
age and 104 genes at 9 
weeks of age were 
differentially 
expressed in SHR 
compared with WKY 
in renal gene 
expression.
Seubert et 
al. (55) 
SHR, spontaneously hypertensive rats. WKY, Wistar-Kyoto rats, usually used for the control the 
experimental group. WTR, wild-type rats. BNR, Brown Norway rats. LHR, Lyon hypertensive rats. 
SDR, Sprague-Dawley rats.  
Table 2. Animals’ microarray studies utilizing target organ tissue. 
3. Summary and conclusions 
Gene expression profiling provides a phenotypic resolution not feasible with standard clinical 
criteria. Differences in the gene expression profiles found in these studies identify markers 
useful for diagnostic, prognostic and therapeutic purposes. These findings emphasize the 
utility of whole blood and target organs as surrogate tissues for gene expression profiling. 
Gene expression profiling of different animal models of essential hypertension, and 
comparison of these profiles with human essential hypertension, will assist in determining the 
complex pathways that comprise the pathobiology of essential hypertension and help with the 
diagnostic, prognostic and therapeutic purposes in the future. 
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